Treasury rumored to consider rule limiting U.S. investment in Chinese biotech
A report says the U.S. Treasury is expected to propose a regulation that would curb American investment in China’s biotech sector. The story notes the proposal is still a rumor and no formal rule has been released.
If enacted, the rule could affect venture capital and other funding streams that target Chinese biotech firms, potentially reshaping cross‑border collaborations. Industry observers are watching the development for its possible impact on financing and market dynamics.
The article also references other biotech news, such as upcoming data from Moderna and Merck at ESMO and telehealth companies exploring GLP‑1 drugs for addiction, but the focus remains on the potential Treasury action.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?”
read at STAT ↗
comments(0)
5-min edit window · permanent after that